During the past decade, Universitatsklinikum Mannheim conducted 138 clinical trials. In the 10-year time frame, 138 clinical trials started and 41 clinical trials were completed, i.e. on average, 29.7% percent of trials that started reached the finish line to date. In the past 5 years, 64 clinical trials started and 32 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitatsklinikum Mannheim" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 19 trials, followed by "Hoffmann-La Roche" with 10 trials sponsored, "Boehringer Ingelheim" with 8 trials sponsored, "Universitätsmedizin Mannheim" with 8 trials sponsored and "Celgene" with 8 trials sponsored. Other sponsors include 174 different institutions and companies that sponsored additional 128 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitatsklinikum Mannheim" #1 collaborator was "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" with 6 trials as a collaborator, "Roche Pharma AG" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Hoffmann-La Roche" with 3 trials as a collaborator and "Novartis" with 3 trials as a collaborator. Other collaborators include 148 different institutions and companies that were collaborators in the rest 141 trials.

According to Clinical.Site data, the most researched conditions in "Universitatsklinikum Mannheim" are "Melanoma" (9 trials), "Crohn Disease" (7 trials), "Prostate Cancer" (6 trials), "Acute Myeloid Leukemia" (5 trials) and "Crohn's Disease" (5 trials). Many other conditions were trialed in "Universitatsklinikum Mannheim" in a lesser frequency.

Most popular intervention types in "Universitatsklinikum Mannheim" are "Drug" (164 trials), "Biological" (26 trials), "Device" (25 trials), "Other" (21 trials) and "Procedure" (17 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Nivolumab" (7 trials), "Gemcitabine" (6 trials), "Carboplatin" (4 trials) and "Etrolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Universitatsklinikum Mannheim" are 211 trials for "All" genders, 12 trials for "Male" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Universitatsklinikum Mannheim". undefined are not yet recruiting, 44 are recruiting, 40 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 98 completed trials in Universitatsklinikum Mannheim, undefined suspended trials, and 31 terminated clinical trials to date.

Out of the total trials that were conducted in Universitatsklinikum Mannheim, 11 "Phase 1" clinical trials were conducted, 68 "Phase 2" clinical trials and 99 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 19 trials that are defined as “Not Applicable".

Universitatsklinikum Mannheim has several departments that took part in Clinical trials: "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie" - 12 trials, "Department of Radiotherapy University Hospital Mannheim" - 7 trials, "Tagestherapiezentrum am ITM Universitätsmedizin Mannheim" - 5 trials, "Medizinische Fakultät Mannheim, Universitätsklinikum Mannheim, Klinik für Urologie" - 3 trials, "University Hospial of Mannheim" - 2 trials, "University Hospital Mannheim, Neurology Clinic" - 3 trials, "Orthopädisch-Unfallchirurgisches Zentrum" - 2 trials, "Universitätsklinikum Mannheim, Tagestherapiezentrum, Interdisziplinäres Tumorzentrum" - 2 trials, "Klinikum Mannheim gGmbH, Kinderklinik, Abt. Hämatologie/Onkologie" - 2 trials